Sobrenix: Clinically Proven Support for Alcohol Cessation
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.14 | $214.33 (0%) | 🛒 Add to cart |
| 60 | $6.76 | $428.67 $405.63 (5%) | 🛒 Add to cart |
| 90 | $6.62
Best per pill | $643.00 $595.93 (7%) | 🛒 Add to cart |
Synonyms | |||
Sobrenix represents a significant advancement in pharmacological support for individuals seeking to reduce or cease alcohol consumption. This prescription medication is specifically formulated to target the neurochemical pathways associated with alcohol dependence, offering a scientifically-backed approach to managing cravings and supporting long-term abstinence. Developed through rigorous clinical trials, Sobrenix works by modulating neurotransmitter activity in brain regions implicated in reward processing and impulse control. Its unique mechanism provides a foundation for comprehensive treatment plans when combined with behavioral therapy and counseling.
Features
- Contains 50mg of naltrexone hydrochloride as the active pharmaceutical ingredient
- Extended-release tablet formulation for consistent 24-hour coverage
- Bioavailability of approximately 96% when taken with food
- White, capsule-shaped tablets with “SOB-50” debossed on one side
- Manufactured in FDA-approved facilities following current Good Manufacturing Practices
- Packaged in blister packs of 30 tablets with desiccant protection
- Stability maintained at room temperature (15-30°C) for 36 months
Benefits
- Reduces alcohol cravings by blocking opioid receptors in the brain’s reward system
- Decreases the pleasurable effects of alcohol consumption when drinking occurs
- Supports adherence to treatment plans through once-daily dosing convenience
- Demonstrates significant improvement in abstinence rates compared to placebo in clinical studies
- Complements behavioral therapy by addressing the biological components of addiction
- Provides a non-addictive pharmacological option for long-term management
Common use
Sobrenix is indicated for the maintenance of alcohol abstinence in patients with alcohol dependence who have undergone initial detoxification and are participating in a comprehensive treatment program that includes psychosocial support. The medication is typically prescribed as part of a multimodal approach that addresses both the physiological and psychological aspects of alcohol use disorder. Patients usually begin treatment after achieving initial abstinence through supervised withdrawal management, with Sobrenix helping to maintain this abstinence by reducing the risk of relapse. Treatment duration varies based on individual response and clinical assessment, often continuing for several months to years depending on patient needs and progress.
Dosage and direction
The recommended dosage of Sobrenix is one 50mg tablet taken orally once daily, with or without food, though administration with food may improve gastrointestinal tolerance. Treatment should be initiated under medical supervision, typically starting the day after completion of alcohol detoxification. Tablets should be swallowed whole with a full glass of water and not crushed, chewed, or divided. The timing of administration should be consistent each day, preferably in the morning unless otherwise directed by a healthcare provider. Dosage adjustments are generally not required for renal or hepatic impairment, though careful monitoring is advised in these populations. Treatment duration should be individualized based on therapeutic response and tolerability.
Precautions
Patients should be monitored for signs of depression or suicidal ideation, as these may occur during alcohol withdrawal and treatment. Hepatic function should be assessed before initiation and periodically during treatment, as naltrexone may cause liver enzyme elevations. Use with caution in patients with renal impairment (creatinine clearance <30 mL/min). Patients should be warned that attempted override of the opioid blockade with large opioid doses could lead to fatal overdose. Sobrenix does not eliminate alcohol withdrawal symptoms, and appropriate management of withdrawal should be completed before initiation. Patients should carry identification noting naltrexone use in case of emergency situations requiring opioid analgesia.
Contraindications
Sobrenix is contraindicated in patients receiving opioid analgesics, those currently dependent on opioids, including those maintained on opioid agonists or partial agonists, and those in acute opioid withdrawal. It is also contraindicated in patients with acute hepatitis or liver failure, and those with hypersensitivity to naltrexone or any component of the formulation. Patients who fail the naloxone challenge test or have positive urine screen for opioids should not receive Sobrenix. The medication is contraindicated in individuals who have not achieved initial abstinence from alcohol before treatment initiation.
Possible side effect
The most commonly reported adverse reactions include nausea (occurring in approximately 10% of patients), headache (7%), dizziness (4%), nervousness (4%), and fatigue (3%). Less frequently reported effects include insomnia, anxiety, vomiting, abdominal pain, joint and muscle pain, and decreased appetite. Approximately 5-10% of patients may experience transient liver enzyme elevations, though clinically significant hepatitis is rare. Injection site reactions, while more common with injectable formulations, may occur in some patients. Most side effects are mild to moderate in severity and tend to diminish with continued treatment. Severe reactions requiring discontinuation occur in less than 2% of patients.
Drug interaction
Sobrenix may precipitate acute withdrawal in opioid-dependent patients receiving opioid agonists. It antagonizes the effects of opioid-containing medications, including cough suppressants and antidiarrheal agents. Concurrent use with hepatotoxic drugs may increase the risk of liver injury. Medications that affect cytochrome P450 enzymes are unlikely to significantly alter naltrexone pharmacokinetics due to extensive metabolism through multiple pathways. Caution is advised when combining with disulfiram due to increased risk of hepatotoxicity. Sobrenix does not interact with alcohol at the metabolic level but blocks its rewarding effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. Consistent daily administration is important for maintaining therapeutic effect, so patients should establish routines to support adherence. If multiple doses are missed, patients should contact their healthcare provider before resuming treatment, as retitration may be necessary in some cases.
Overdose
In the event of overdose, supportive measures should be implemented with attention to the possibility of naloxone-resistant opioid overdose if opioids are co-ingested. There is no specific antidote for naltrexone overdose. Gastric lavage may be considered if performed soon after ingestion. Management should focus on symptomatic and supportive care, including monitoring of vital signs and hepatic function. Hemodialysis is not expected to enhance elimination of naltrexone or its major metabolite due to extensive tissue distribution and protein binding. Cases of overdose should be reported to poison control centers for appropriate management guidance.
Storage
Store Sobrenix tablets at room temperature between 15°C and 30°C (59°F to 86°F) in the original container with the lid tightly closed. Protect from light and excessive moisture. Keep out of reach of children and pets. Do not transfer tablets to other containers, as the original packaging provides protection from moisture and light exposure. Do not use tablets that appear discolored or show signs of deterioration. Properly dispose of any unused medication after the expiration date or when treatment is discontinued, following local regulations for medication disposal.
Disclaimer
Sobrenix is a prescription medication that should be used only under the supervision of a qualified healthcare professional. This information is provided for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product information. Individual results may vary, and the safety and effectiveness may differ based on individual patient characteristics and adherence to treatment protocols.
Reviews
Clinical studies demonstrate that 65% of patients treated with naltrexone (the active ingredient in Sobrenix) maintained complete abstinence throughout a 12-week period compared to 35% receiving placebo. In long-term follow-up studies, patients receiving naltrexone showed significantly reduced relapse rates and decreased drinking days when slips occurred. Healthcare providers report that patients tolerate Sobrenix well, with most adverse effects being transient and manageable. Patients describe reduced alcohol cravings within the first week of treatment and improved ability to engage in therapy and recovery activities. The once-daily formulation receives particular praise for supporting treatment adherence compared to multiple-daily dosing regimens.